What is the recommended management of hepatorenal syndrome?

Management of Hepatorenal Syndrome

The treatment of choice for hepatorenal syndrome-acute kidney injury (HRS-AKI) is terlipressin combined with intravenous albumin, administered as either IV bolus or continuous infusion. 1

First-Line Pharmacologic Management

Vasoconstrictor Therapy with Albumin

• Terlipressin plus albumin is the preferred regimen for HRS-AKI, with demonstrated superiority in reversing HRS compared to placebo (43% vs 17% reversal rate in patients without ACLF grade 3 or creatinine ≥5 mg/dL) 2
• Terlipressin shows higher HRS reversal rates than alternative treatments including midodrine/octreotide and norepinephrine 3
• Response is defined as creatinine decreasing to <1.5 mg/dL or returning to within 0.3 mg/dL of baseline over a maximum of 14 days 1

Alternative Vasoconstrictors (When Terlipressin Unavailable)

• Norepinephrine should be used when terlipressin is not available 1
• If neither terlipressin nor norepinephrine can be administered, consider oral midodrine (5-15 mg every 8 hours) combined with octreotide (100-200 μg every 8 hours or 50 μg/hour IV), though efficacy is low 1

Treatment Monitoring and Duration

Response Assessment

• Monitor creatinine levels closely during treatment 1
• If creatinine remains at or above pretreatment level after 4 days with maximum tolerated vasoconstrictor doses, therapy may be discontinued 1
• Treatment duration extends up to 14 days maximum for response assessment 1

Critical Safety Monitoring

• Closely monitor for ischemic complications and pulmonary edema during vasoconstrictor and albumin therapy 1
• Patients with volume overload or ACLF grade 3 have elevated risk of respiratory failure with terlipressin 2
• When excluding high-risk patients (ACLF grade 3 or creatinine ≥5 mg/dL), respiratory failure rates are similar between terlipressin and placebo (11% vs 7%) 2

Recurrence Management

• Recurrence after treatment discontinuation should be retreated with the same vasoconstrictor-albumin regimen 1

Renal Replacement Therapy (RRT)

Indications for RRT

• Use RRT in liver transplant candidates with worsening renal function, electrolyte disturbances, or increasing volume overload unresponsive to vasoconstrictor therapy 1
• For non-transplant candidates, initiate RRT only with a clear endpoint in mind, as mortality rates are extremely high regardless of whether AKI was due to HRS or ATN 1
• A limited trial of RRT may be considered in selected non-transplant patients depending on reversibility of other organ failures 1

Liver Transplantation Considerations

Urgent Evaluation

• All patients with cirrhosis and AKI should be considered for urgent liver transplant evaluation given high short-term mortality even in responders to vasoconstrictors 1
• Successful HRS-AKI treatment reduces MELD scores due to improved creatinine, which may disadvantage patients on transplant waiting lists despite not translating to meaningful survival gains 1

Simultaneous Liver-Kidney Transplantation

• Simultaneous liver-kidney transplantation may be necessary for patients not expected to recover kidney function post-transplantation 1

Multidisciplinary Decision-Making

• Management decisions including initiation of vasoconstrictor therapy and RRT should be made by multidisciplinary teams including hepatology, nephrology, critical care, and transplant surgery specialists 1
• This collaborative approach is essential given the complexity of HRS-AKI diagnosis and management 4

Common Pitfalls to Avoid

• Do not delay treatment initiation—early vasoconstrictor therapy improves outcomes 5
• Avoid using terlipressin in patients with ACLF grade 3 or baseline creatinine ≥5 mg/dL due to unfavorable benefit-to-risk profile 2
• Do not assume improved creatinine after treatment means improved transplant candidacy—MELD score reduction may disadvantage patients on waiting lists 1
• Recognize that absence of proteinuria or hematuria does not exclude intrinsic renal damage in cirrhotic patients 5